# Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.

> **NCT01214889** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 370 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Poliomyelitis
- Haemophilus Influenzae Type B

## Interventions

- **BIOLOGICAL:** PENTAXIM™: DTacP IPV//PRP~T combined vaccine
- **BIOLOGICAL:** TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine

## Key facts

- **NCT ID:** NCT01214889
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-11
- **Final completion:** 2011-12
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2012-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01214889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01214889, "Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01214889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*